ProfileGDS5678 / 1420745_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 90% 90% 91% 91% 91% 91% 92% 91% 90% 91% 90% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.1915690
GSM967853U87-EV human glioblastoma xenograft - Control 27.2581390
GSM967854U87-EV human glioblastoma xenograft - Control 37.3334890
GSM967855U87-EV human glioblastoma xenograft - Control 47.6624591
GSM967856U87-EV human glioblastoma xenograft - Control 57.4079791
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1053391
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.1778691
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4833792
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4069491
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.323690
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2983391
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.307690
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4192191
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3241291